Rapid Diagnostic Test Evaluated for Yaws Infection
By LabMedica International staff writers Posted on 29 Sep 2014 |

Image: A primary yaws skin lesion on an infant patient’s leg (Photo courtesy of Dr. Oriol Mitjá).
The development of a rapid diagnostic test (RDT) for serological diagnosis in the isolated communities affected by yaws is a key requirement for the successful implementation of the global control strategy.
Yaws is a non-venereal treponemal infection caused by a spirochete bacterium Treponema pallidum ssp. pertenue (T. pertenue) which is currently thought to be endemic in fourteen countries and the emergence of azithromycin as an effective oral agent in the treatment of yaws has prompted renewed calls for a coordinated worldwide program to eradicate the disease.
Scientists the London School of Hygiene & Tropical Medicine (UK) working with colleagues from the Solomon Islands evaluated the utility of a Dual Path Platform (DPP) test in screening for yaws, utilizing samples collected as part of a community prevalence survey conducted in the Solomon Islands. The sera from four hundred and fifteen samples were randomly selected. The median age was 9 years, and 52.1% of participants were male. Individuals selected for this study did not differ significantly from the larger prevalence survey population with regards to demographic or clinical features. Clinical findings consistent with active and healed yaws were found in 19 (4.7%) and 34 (8.2%) respectively of the 415 participants.
Sera were tested using traditional syphilis tests, the Treponema pallidum particle agglutination assay (TPPA, Mast Diagnostics; Merseyside, UK) and a quantitative Rapid Plasma Reagin assay (RPR, Deben Diagnostics; Sheffield, UK) and the new RDT, the DPP Syphilis Screen and Confirm (Chembio; Medford, NY, USA). The investigators found 123 (29.6%) individuals had a reactive TPPA and120 (28.9%) individuals had a reactive RPR at any titer. By gold standard serology there were 18 individuals with a false positive RPR, defined as a positive RPR and negative TPPA. All false positive RPRs in the study had an RPR titer of 1:2. The overall prevalence of true RPR reactivity was therefore 102/415 (24.6%). The sensitivity of the DPP was strongly related to the RPR titer with a sensitivity of 92.0% for an RPR titer of greater than 1:16.
The authors concluded that the DPP test can be used as part of a community surveillance strategy to identify individuals who are dually seropositive with high-titer RPRs. These individuals are most likely to represent the major source of ongoing transmission. Wider access to DPP testing would improve the awareness of worldwide yaws case reporting and the test may play a key role in assessing patients presenting with yaws like lesions in a post-mass drug administration (MDA) setting. The study was published on September 11, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
London School of Hygiene & Tropical Medicine
Mast Diagnostics
Deben Diagnostics
Yaws is a non-venereal treponemal infection caused by a spirochete bacterium Treponema pallidum ssp. pertenue (T. pertenue) which is currently thought to be endemic in fourteen countries and the emergence of azithromycin as an effective oral agent in the treatment of yaws has prompted renewed calls for a coordinated worldwide program to eradicate the disease.
Scientists the London School of Hygiene & Tropical Medicine (UK) working with colleagues from the Solomon Islands evaluated the utility of a Dual Path Platform (DPP) test in screening for yaws, utilizing samples collected as part of a community prevalence survey conducted in the Solomon Islands. The sera from four hundred and fifteen samples were randomly selected. The median age was 9 years, and 52.1% of participants were male. Individuals selected for this study did not differ significantly from the larger prevalence survey population with regards to demographic or clinical features. Clinical findings consistent with active and healed yaws were found in 19 (4.7%) and 34 (8.2%) respectively of the 415 participants.
Sera were tested using traditional syphilis tests, the Treponema pallidum particle agglutination assay (TPPA, Mast Diagnostics; Merseyside, UK) and a quantitative Rapid Plasma Reagin assay (RPR, Deben Diagnostics; Sheffield, UK) and the new RDT, the DPP Syphilis Screen and Confirm (Chembio; Medford, NY, USA). The investigators found 123 (29.6%) individuals had a reactive TPPA and120 (28.9%) individuals had a reactive RPR at any titer. By gold standard serology there were 18 individuals with a false positive RPR, defined as a positive RPR and negative TPPA. All false positive RPRs in the study had an RPR titer of 1:2. The overall prevalence of true RPR reactivity was therefore 102/415 (24.6%). The sensitivity of the DPP was strongly related to the RPR titer with a sensitivity of 92.0% for an RPR titer of greater than 1:16.
The authors concluded that the DPP test can be used as part of a community surveillance strategy to identify individuals who are dually seropositive with high-titer RPRs. These individuals are most likely to represent the major source of ongoing transmission. Wider access to DPP testing would improve the awareness of worldwide yaws case reporting and the test may play a key role in assessing patients presenting with yaws like lesions in a post-mass drug administration (MDA) setting. The study was published on September 11, 2014, in the journal Public Library of Science Neglected Tropical Diseases.
Related Links:
London School of Hygiene & Tropical Medicine
Mast Diagnostics
Deben Diagnostics
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Blood Test Could Predict Relapse of Autoimmune Blood Vessel Disease
Neutrophils, once believed to be uniform in nature, have been discovered to exhibit significant diversity. These immune cells, which play a crucial role in fighting infections, are also implicated in autoimmune... Read more
First-of-its-Kind Blood Test Detects Trauma-Related Diseases
In today’s fast-paced world, stress and trauma have unfortunately become common experiences for many individuals. Continuous exposure to stress hormones can confuse the immune system, causing it to misinterpret... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more
World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
Thyroid cancer is one of the most common cancers worldwide, and its precise management typically relies on two primary systems: (1) the 8th edition of the American Joint Committee on Cancer (AJCC) or ... Read more
Breakthrough Diagnostic Approach to Significantly Improve TB Detection
Tuberculosis (TB) remains the deadliest infectious disease globally, with 10.8 million new cases and 1.25 million deaths reported in 2023. Early detection through effective screening is crucial in identifying... Read more
Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
Genetic testing has been an important method for detecting infectious diseases, diagnosing early-stage cancer, ensuring food safety, and analyzing environmental DNA. For a long time, polymerase chain reaction... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more